oral decitabine

DRUG2 trials

Sponsors

Case Comprehensive Cancer Center, Massachusetts General Hospital

Conditions

Head and Neck CancerLung CancerNon-small Cell Lung Cancer

Phase 1

Oral Decitabine (ASTX727) and Durvalumab in Recurrent and/or Metastatic Head and Neck Cancer Patients

CompletedNCT03019003

Massachusetts General HospitalHead and Neck Cancer

Start: 2017-03-20End: 2024-09-24Updated: 2025-09-16

Phase 2

Rational EpigenetiC Immunotherapy for SEcond Line Therapy in Patients With NSCLC: PRECISE Trial

CompletedNCT02664181

Case Comprehensive Cancer CenterLung Cancer, Non-small Cell Lung Cancer

Start: 2017-06-06End: 2024-05-19Updated: 2024-09-03

Related Papers

Epigenetic therapy sensitizes anti–PD-1 refractory head and neck cancers to immunotherapy rechallenge

Journal of Clinical Investigation2025-03-1612 citations

Tetrahydrouridine/decitabine/5-azacytidine for non-cytotoxic epigenetic-immunotherapy of NSCLC in vivo.

Journal of Clinical Oncology2018-05-204 citations

Tetrahydrouridine-decitabine for non-cytotoxic epigenetic therapy of NSCLC to enhance immunotherapeutic effect of anti-PD1 in vivo.

Journal of Clinical Oncology2017-05-202 citations

Pre-clinical proof of principle of pharmacologically rational non-cytotoxic epigenetic-immunotherapy to treat lung cancer.

Journal of Clinical Oncology2016-05-20